Evidence map›Paper›PMID 37502123›Full record

ArticleApplied sciences (Basel, Switzerland)2022

Rapid Detection of Direct Compound Toxicity and Trailing Detection of Indirect Cell Metabolite Toxicity in a 96-Well Fluidic Culture Device for Cell-Based Screening Environments: Tactics in Six Sigma Quality Control Charts.

Bob Lubamba, Timothy Jensen, Randall McClelland

Abstract read
In one paragraph

Article in Applied sciences (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bob LubambaSciBioix, 6409 Fayetteville Rd., Suite 120#64, Durham, NC 27713, USA.
Timothy JensenSciKon Innovation, Inc., P.O. Box 9100, Chapel Hill, NC 27515, USA.
Randall McClellandSciKon Innovation, Inc., P.O. Box 9100, Chapel Hill, NC 27515, USA.ORCID 0000-0002-7166-5750

Funding

Standardization of a Fluidic In Vitro Exposure System for IVIVE Predictive Toxicity DataR44GM123796 · NIGMS · SCIKON INNOVATION, INC. · PI MCCLELLAND, RANDALL EDWIN, MOSEDALE, MERRIE · 2017 to 2018
$1.6M
Low Cost Microphysiological System for Improved PharmacodynamicsR43GM117954 · NIGMS · SCIKON INNOVATION, INC. · PI MCCLELLAND, RANDALL EDWIN · 2016 to 2016
$200k
Bench-top human metabolism system for improved IVIVE in drug developmentR43ES025970 · NIEHS · SCIKON INNOVATION, INC. · PI MCCLELLAND, RANDALL EDWIN · 2015 to 2015
$169k
NIEHS NIH HHS R43 ES025970NIGMS NIH HHS R43 GM117954NIGMS NIH HHS R44 GM123796
6 · The paper itself

Abstract

Microfluidic screening tools,

Indexed as

cell metabolite toxicitycompound toxicitydrug discoveryhepatoxicityin vitrolivermicrofluidicsmultiwellpredictivityscreening

Identifiers

PMID37502123
PMCPMC10374175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.